Sanofi
NASDAQ Global SelectCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Belén Garijo López
- Full Time Employees
- 82,878
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- Address
- 46, Avenue de la Grande-Armée Paris IF France 75008
- IPO Date
- Jul 1, 2002
- CIK
- 0001121404
- Website
- sanofi.com
- Similar Companies
- Business
- Sanofi is a global biopharmaceutical leader involved in the exploration, development, manufacturing, and commercialization of diverse therapeutic solutions across various international markets. The company operates primarily through its focused segments of Pharmaceuticals and Vaccines, undergoing a strategic evolution to center on innovative biopharmaceutical advancements. Within its Pharmaceutical division, Sanofi delivers specialized care products, including advanced treatments for immunology, such as human monoclonal antibodies, and therapies addressing multiple sclerosis, other neurological conditions, inflammatory diseases, rare disorders, oncology, and specific rare blood conditions. The Vaccines segment remains a cornerstone, providing immunizations for diseases like poliomyelitis, pertussis, influenza, meningitis, and other booster and travel-related vaccines, serving populations globally. In a significant strategic realignment, Sanofi has moved to divest a controlling stake in its Consumer Healthcare unit, Opella, to intensify its focus on high-growth biopharma areas and enhance its research and development capabilities. The company generates revenue predominantly through the sale of its innovative pharmaceutical products and vaccines, complemented by income from licensing agreements, collaborations, and strategic partnerships. Its target market includes a broad spectrum of healthcare providers, such as hospitals, clinics, and pharmacies, alongside patients requiring specialized medical care. Recent initiatives highlight Sanofi's commitment to scientific breakthroughs, with substantial investments in research and development, particularly in immunology and oncology. Key developments include the acquisition of Inhibrx in early 2024 to bolster its rare disease pipeline, a collaboration with Orano Med in late 2024 for next-generation radioligand therapies in oncology, and the buyout of Vigil Neuroscience in May 2025. Furthermore, Sanofi Ventures committed additional capital in September 2025 to foster early-stage biotech and digital health innovations. Its robust pipeline currently features 93 clinical-stage projects, with 36 in Phase 3 or under regulatory review as of October 2025. The company also achieved a positive CHMP recommendation in November 2025 for Teizeild (teplizumab) for stage 2 type 1 diabetes in the European Union. Sanofi was established in 1973 and maintains its headquarters in Paris, France.
Aqemia and Sanofi Expand Their Research Collaboration
3 High-Yield Dividend Stocks to Buy and Hold
Press Release: Sanofi's subcutaneous Sarclisa Escena approved in the US as first anticancer treatment administered via on-body injector
US FDA approves Sanofi's wearable injector form of blood cancer drug
EU seeks feedback on Sanofi's commitments addressing suspected anti-competitive behaviour
SNY's Nexviazyme Meets Goals in Infantile-Onset Pompe Disease Study
Press Release: Availability of the aide-mémoire for Q2 2026 results
Bargain Hunters: These 3 High-Yielding Stocks Recently Hit New 52-Week Lows
Recursion Pharmaceuticals vs. Summit Therapeutics: Which Healthcare Stock Is a Better Buy in 2026?
EU Commission opens antitrust probe into Sanofi's flu vaccine campaign
Is AbbVie a Buy After Its Purchase of Apogee?
Sanofi: Dupixent Risks Overstated, Valuation Disconnect Creates Opportunity
Press Release: Sanofi Foundation opens new chapter centered on future generations
EU Clears SNY's Cenrifki for Secondary Progressive Multiple Sclerosis
Sanofi Multiple Sclerosis Drug Gets EU Approval
Press Release: Sanofi's Wayrilz approved in Japan to treat immune thrombocytopenia
Can Sanofi Rely on Dupixent to Drive Long-Term Revenue Growth?
Press Release: Sanofi appoints Paulo Fontoura as Global Head of R&D
Press Release: Sanofi's Sarclisa subcutaneous formulation approved in Japan for patients with multiple myeloma
Sanofi 'Strong Buy': Continued Dupxient Sales Growth And Sarclisa OBI First